Angiogenic factors in maternal circulation and the risk of severe fetal growth restriction.

Maternal angiogenic factors (placental growth factor, soluble fms-like tyrosine kinase 1 (Flt-1), and soluble endoglin) may be associated with fetal growth restriction, and the associations may differ according to stage of pregnancy. Among children born to pregnant women without preeclampsia in Norway between 1992 and 1994, 217 singletons with severe growth restriction (small for gestational age (SGA), <2.5th percentile) were compared with 378 singleton controls. For each angiogenic factor, SGA risk was related to concentrations in maternal serum collected in the first 2 trimesters, by using women with a serum concentration in the middle third at both samplings as reference. A low placental growth factor (lowest third) at both samplings was associated with high risk of SGA (odds ratio=3.8, 95% confidence interval: 1.6, 8.8). An increase from the lowest to the highest third of soluble Flt-1 was associated with high SGA risk (odds ratio=6.2, 95% confidence interval: 2.4, 16.1). Women with high soluble endoglin (highest third) at the second sampling had approximately a 3.5-fold increased risk of SGA. Low maternal soluble Flt-1 in early pregnancy followed by a strong subsequent increase in soluble Flt-1 and soluble endoglin was associated with a particularly high risk of severe fetal growth restriction.

[1]  Gordon C. S. Smith,et al.  The perinatal implications of angiogenic factors , 2009, Current opinion in obstetrics & gynecology.

[2]  K. Nicolaides,et al.  Maternal serum placental growth factor (PlGF) in small for gestational age pregnancy at 11+0 to 13+6 weeks of gestation , 2008, Prenatal diagnosis.

[3]  A. Diab,et al.  Angiogenic factors for the prediction of pre‐eclampsia in women with abnormal midtrimester uterine artery Doppler velocimetry , 2008, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[4]  L. Thaete,et al.  The fetal response to chronic placental insufficiency. , 2008, Seminars in perinatology.

[5]  T. Sørensen,et al.  Weight at Birth and All-Cause Mortality in Adulthood , 2008, Epidemiology.

[6]  F. Epstein,et al.  Preeclampsia and angiogenic imbalance. , 2008, Annual review of medicine.

[7]  Wenjiang J. Fu,et al.  A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate , 2008, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[8]  Wenjiang J. Fu,et al.  The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age , 2008, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[9]  H. Stepan,et al.  Maternal plasma concentrations of soluble endoglin in pregnancies with intrauterine growth restriction. , 2007, The Journal of clinical endocrinology and metabolism.

[10]  L. Vatten,et al.  Changes in circulating level of angiogenic factors from the first to second trimester as predictors of preeclampsia. , 2007, American journal of obstetrics and gynecology.

[11]  A. Hingorani,et al.  Maternal serum concentration of soluble fms-like tyrosine kinase 1 and vascular endothelial growth factor in women with abnormal uterine artery Doppler and in those with fetal growth restriction. , 2006, American journal of obstetrics and gynecology.

[12]  C. Kanaka-Gantenbein,et al.  Causes of Intrauterine Growth Restriction and the Postnatal Development of the Metabolic Syndrome , 2006, Annals of the New York Academy of Sciences.

[13]  B. Sibai,et al.  Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. , 2006, The New England journal of medicine.

[14]  E. Gratacós,et al.  Placental angiogenic growth factors and uterine artery Doppler findings for characterization of different subsets in preeclampsia and in isolated intrauterine growth restriction. , 2006, American journal of obstetrics and gynecology.

[15]  T. Libermann,et al.  Soluble endoglin contributes to the pathogenesis of preeclampsia , 2006, Nature Medicine.

[16]  D. Hassiakos,et al.  Soluble vascular endothelial growth factor receptor-1 in intrauterine growth restricted fetuses and neonates. , 2006, Early human development.

[17]  P. Jenum,et al.  Maternal antibodies against cytomegalovirus in pregnancy and the risk of fetal death and low birth weight , 2005, Acta obstetricia et gynecologica Scandinavica.

[18]  R. Ness,et al.  Soluble fms-like tyrosine kinase 1 is increased in preeclampsia but not in normotensive pregnancies with small-for-gestational-age neonates: relationship to circulating placental growth factor. , 2005, The Journal of clinical endocrinology and metabolism.

[19]  Peter Gluckman,et al.  Developmental plasticity and human health , 2004, Nature.

[20]  Robert N. Taylor,et al.  First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. , 2004, The Journal of clinical endocrinology and metabolism.

[21]  J. Foidart,et al.  Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. , 2003, The Journal of clinical endocrinology and metabolism.

[22]  T. Libermann,et al.  Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia , 2003 .

[23]  K. Alitalo,et al.  Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. , 2002, The American journal of pathology.

[24]  H. Gjessing,et al.  Birthweight by gestational age in Norway , 2000, Acta obstetricia et gynecologica Scandinavica.

[25]  K. Leveno,et al.  Birth weight in relation to morbidity and mortality among newborn infants. , 1999, The New England journal of medicine.

[26]  A. N. Corps,et al.  A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation. , 1998, Biology of reproduction.

[27]  B. Stray-Pedersen,et al.  Incidence of Toxoplasma gondii Infection in 35,940 Pregnant Women in Norway and Pregnancy Outcome for Infected Women , 1998, Journal of Clinical Microbiology.

[28]  Jing Xu,et al.  Placental expression of soluble fms-like tyrosine kinase 1 is increased in singletons and twin pregnancies with intrauterine growth restriction. , 2008, The Journal of clinical endocrinology and metabolism.

[29]  S. Karumanchi,et al.  Molecular mechanisms of preeclampsia. , 2008, Microvascular research.

[30]  M. Post,et al.  Severe intrauterine growth restriction pregnancies have increased placental endoglin levels: hypoxic regulation via transforming growth factor-beta 3. , 2008, The American journal of pathology.

[31]  L. Shulman.  Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor , 2008 .

[32]  R. Wong.  Circulating Angiogenic Factors in Early Pregnancy and the Risk of Preeclampsia, Intrauterine Growth Restriction, Spontaneous Preterm Birth, and Stillbirth , 2008 .

[33]  M. Beckmann,et al.  Angiogenic growth factors in maternal and fetal serum in pregnancies complicated by intrauterine growth restriction. , 2007, Clinical science.

[34]  U. Stenman,et al.  Maternal serum-soluble vascular endothelial growth factor receptor-1 in early pregnancy ending in preeclampsia or intrauterine growth retardation. , 2006, The Journal of clinical endocrinology and metabolism.

[35]  Robert N. Taylor,et al.  Longitudinal serum concentrations of placental growth factor: evidence for abnormal placental angiogenesis in pathologic pregnancies. , 2003, American journal of obstetrics and gynecology.

[36]  吉松淳,et al.  Soluble fms‐like tyrosine kinase 1による血管内皮細胞増殖能の抑制に関する検討 , 2003 .